US 12,263,161 B2
Bupropion dosage forms with reduced food and alcohol dosing effects
Herriot Tabuteau, New York, NY (US)
Assigned to ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed by ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed on Jan. 17, 2024, as Appl. No. 18/415,196.
Application 18/415,196 is a continuation of application No. 18/353,323, filed on Jul. 17, 2023, granted, now 11,925,636.
Application 18/353,323 is a continuation of application No. 18/157,393, filed on Jan. 20, 2023, granted, now 11,717,518, issued on Aug. 8, 2023.
Claims priority of provisional application 63/370,771, filed on Aug. 8, 2022.
Claims priority of provisional application 63/370,590, filed on Aug. 5, 2022.
Claims priority of provisional application 63/357,521, filed on Jun. 30, 2022.
Prior Publication US 2024/0148719 A1, May 9, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/24 (2006.01); A61K 9/20 (2006.01); A61K 31/138 (2006.01); A61K 31/485 (2006.01)
CPC A61K 31/485 (2013.01) [A61K 9/2027 (2013.01); A61K 9/2086 (2013.01); A61K 31/138 (2013.01)] 22 Claims
 
1. A method of treating agitation associated with Alzheimer's disease in a human patient who is consuming alcohol, comprising administering, twice a day, a dosage form to a human patient for the treatment of agitation associated with the patient's Alzheimer's disease, and reducing but not discontinuing consumption of alcohol by the human patient, wherein the dosage form comprises 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion, 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another salt form of dextromethorphan or the free base form of dextromethorphan, and a polymer.